The NF-κB transcription factor: Role in oncogenesis and in response to anticancer therapeutics;LE FACTUER TRANSCRIPTIONNEL NF-κB: ROLE AU COURS DE L'ONCOGENESE ET DE LA REPONSE AU TRAITEMENT ANTICANCEREUX

Medecine/Sciences

Volumn 14, Issue 5, 1998, Pages 566-571

  Bours, Vincent ^a,b   Dejardin, Emmanuel ^a,b   Bonizzi, Giuseppina ^b   Merville, Marie Paule ^b   Piette, Jacques ^c  

^a FNRS ^*

^b UNIVERSITY OF LIÈGE   (Belgium)

^c CHU SART TILMAN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ONCOPROTEIN; TRANSCRIPTION FACTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GROWTH; CARCINOGENESIS; DNA DAMAGE; DRUG CYTOTOXICITY; GENE ACTIVATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; REVIEW;

EID: 0031799497     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.4267/10608/1094     Document Type: Review

References (29)

1. Costello R, Lecine P, Kahn-Perlès B, Algarté M, Lipcey C, Olive D, Imbert J. Activation du système de facteurs de transcription Rel/NF-κB. Med Sci 1995; 11: 957-65.
2. Israël A. Les protéines Rel/NF-κB et IκB: nouvelles données sur la structure, la fonction et la régulation. Med Sci 1995; 11: 1017-20.
3. Baeuerle PA, Henkel T. Function and activation of NF-κB in the immune system. Annu Rev Immunol 1994; 12: 141-79.
4. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-κB. Annu Rev Cell Biol 1994; 10: 405-55.
5. Whiteside ST, Epinat JC, Rice NR, Israël A. I kappa B epsilon, a novel member of the IκB family, controls RelA and cRel NF-κB activity. EMBO J 1997; 16: 1413-26.
6. Lenardo M, Siebenlist U. Bcl-3-mediated nuclear regulation of the NF-κB trans-activating factor. Immunol Today 1994; 15: 145-7.
7. Bours V, Franzoso G, Azarenko V, Park S, Kanno T, Brown K, Siebenlist U. The oncoprotein Bcl-3 directly transactivates through κB motifs via association with DNA-binding p50B homodimers. Cell 1993; 72: 729-39.
8. Imbert V, Rupec RA, Livolsi A, Pahl HL, Traenckner EBM, Mueller-Dieckmann C, Farahifar D, Rossi B, Auberger P, Baeuerle PA, Peyron JF. Tvrosine phosphorylation of IκB-α activates NF-κB without proteolytic degradation of IκB-α. Cell 1996; 86: 787-98.
9. Brown K, Park S, Kanno T, Franzoso G, Sibenlist U. Mutual regulation of the transcriptional activator NF-κB and its inhibitor, IκB-α. Proc Natl Acad Sci USA 1993; 90: 2532-6.
10. Luque I, Gélinas C. Rel/NF-κB and IκB factors in oncogenesis. Semin Cancer Biol 1997; 8: 103-11.
11. Gilmore TD, Koedood M, Piffat KA, White DW. Rel/NF-κB/IκB proteins and cancer. Oncogene 1996; 13: 1367-78.
12. Carrasco D, Risso CA, Dorfman K, Bravo R. The v-Rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice. EMBO J 1996; 15: 3640-50.
13. Schouten JG, Van der Eb AJ, Zantema A. Downregulation of MHC class I expression due to interference with p105-NFκB processing by Ad12E1A. EMBO J 1995; 14: 1498-1507.
14. Chang CC, Zhang J, Lombardi L, Neri A, Dalla-Favera R. Rearranged NF-κB2 genes in lymphoid neoplasms code for constitutively active nuclear transactivators. Mol Cell Biol 1995; 15: 5180-7.
15. Beauparlant P, Kwan I, Bitar R, Chou P, Koromilas AE, Sonenberg N, Hiscott J. Disruption of IκBα by antisense RNA expression leads to malignant transformation. Oncogene 1994; 9: 3189-97.
16. Garrido F, Cabrera T, Lopez-Nevot MA, Ruiz-Cabello F. HLA Class I antigens in human tumors. Adv Cancer Res 1995; 67: 155-95.
17. b gene expression in metastatic tumor cells. J Exp Med 1993; 177: 1651-62.
18. Dejardin E, Deregowski V, Greimers R, Cai Z, Chouaib S, Merville MP, Bours V. Regulation of Major Histocompatibility Complex Class I expression by NF-κB-related proteins in breast cancer cells. Oncogene 1998 (sous presse).
19. Cadoret A, Bertrand F, Baron-Delage S, Levy P, Courtois G, Gespach C, Capeau J, Cherqui G. Down-regulation of NF-κB activity and NF-κB p65 subunit expression by ras and polyoma middle T oncogenes in human colonic Caco-2 cells. Oncogene 1997; 14: 1589-600.
20. Dejardin E, Bonizzi G, Bellahcène A, Castronovo V, Merville MP, Bours V. Highly-expressed p100/p52 (NFKB2) sequesters other NF-κB-related proteins in the cytoplasm of human breast cancer cells. Oncogene 1995; 11: 1835-41.
21. Baichwal VR, Baeuerle PA. Apoptosis: activate NF-κB or die? Curr Biol 1997; 7: R94-R96.
22. Beg AA., Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 1996; 274: 782-4.
23. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-α-induced apoptosis by NF-κB. Science 1996; 274: 787-9.
24. Wang CY, Mayo MW, Baldwin AS. TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 1996; 274: 784-7.
25. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature 1995; 376: 167-70.
26. Grimm S, Bauer MKA, Baeuerle PA, Schulze-Osthoff K. Bcl-2 down-regulates the activity of transcription factor NF-κB induced upon apoptosis. J Cell Biol 1996; 134: 13-23.
27. Piette J, Piret B, Bonizzi G, Schoonbroodt S, Merville MP, Legrand-Poels S, Bours V. Multiple redox regulation in NF-κB transcription factor activation. Biol Chem 1997; 378: 1237-45.
28. Hellin AC, Calmant P, Gielen J, Bours V, Merville MP. Nuclear Factor-κB-dependent regulation of p53 gene expression induced by daunomycin genotoxic drug. Oncogene 1998; 16: 1187-96.
29. Piret B, Piette J. Topoisomerase poisons activate the transcription factor NF-κB in ACH-2 and CEM cells. Nucleic Acids Res 1996; 24: 4242-8.